The healthcare sector is usually regarded as one of the safest and most stable spaces in the market, which becomes especially important and attractive during volatile periods such as today in the S...

Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly's obesity and diabetes drugs are no longer fa...

These top stocks are on a winning streak and have the businesses to keep it going.

Shares of Hims & Hers Health (HIMS) sank Thursday after the Food and Drug Administration (FDA) said Eli Lilly's (LLY) popular weight-loss treatments, Mounjaro and Zepbound, were no longer on its li...

Hims & Hers is a fantastic value despite its high 'on-the-surface' P/E ratio and valuation metrics. The company's subscription-based model in healthcare, targeting chronic conditions, ensures recur...

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular weight-loss drug Wegovy to patients in certain professions for $99 a month.

Buying a new pharmacy will allow Hims & Hers to expand into new markets.

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $16.28, moving -1.75% from the previous trading session.

Hims & Hers completed the acquisition of MedisourceRX, a pharmacy that will expand in-house production. The deal included issuing stock, which will ultimately dilute shareholders.

Hims & Hers' business grew by more than 50% last quarter. The company has plenty more growth opportunities to pursue in pain management, fertility, and diabetes.

Traders are often quoted as slaves to volatility, as their entire business model is dependent on stocks moving actively to meet the conditions of a trade and spread. However, long-term value invest...

Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market si...

Funds run by Israel Englander, John Overdeck, and David Siegel bought more than a million shares of Hims & Hers Health in the second quarter. Hims & Hers Health runs a niche telehealth service for ...

Both companies revolve around subscription-based services. Hims & Hers is witnessing high-double-digit growth, and profits are soaring.

Eli Lilly is discounting Zepbound, potentially undercutting a growing business for Hims & Hers. Pharma companies are starting to sell more drugs direct-to-consumer, threatening traditional pharmacies.